New York, New York--(Newsfile Corp. - October 22, 2020) - Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend" or "the Company") (NASDAQ: LEGN) concerning possible violations of federal securities laws.
On September 21, 2020, Legend Biotech announced in a press release that its Chief Executive Officer, Dr. Fangliang Zhang, was under residential surveillance by Chinese law enforcement authorities. It was also disclosed that the Chinese Customs Anti-Smuggling Department has inspected certain business facilities of GenScript Biotech Corporation, Legend's parent and majority shareholder, in relation to suspected violations of import and export regulations under Chinese law.
Following the publication of the report, Legend stock price dropped by as much as 15.8 percent.
To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66678